Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04098627 · ClinicalTrials.gov registry record · NA

The Effects of Laughter Therapy on Hemodialysis on Depression

A NA study, sponsored by Satellite Healthcare.

Completed
Registry status
NA
Development phase
152
Enrollment target

NCT04098627: Completed NA study, sponsored by Satellite Healthcare.

NCT04098627 is a NA study that has completed, run by Satellite Healthcare. The registered enrollment target is 152 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04098627, a NA study, has completed, sponsored by Satellite Healthcare.

COMPLETED
Registry status
NA
Development phase
152 participants
Enrollment target

Study Summary

End stage kidney disease is associated with increased depression. Laughter is associated with improvement in depression in chronic disease. The study objective was to measure the effect of intradialytic group laughter therapy on anxiety and depression. Pragmatic randomized controlled trial conducted in 10 hemodialysis centers in Northern California. The intervention group received a once weekly 30-minute long group laughter therapy session for 8 weeks. Primary outcome was depression score as measured using the Patient Health Questionnaire.

Primary Outcome

Change in General Anxiety Disorder Scale 2 (GAD -2) in intervention group compared to change in the usual care group. The construct is the screening measure of depression which is calculated by the sum of 2 items on a scale of 0 to 3. A score of 3 or greater for depression is considered positive for screening purposes. The higher the sore the greater the chance of depression risk and thus the worse outcome.

Interventions

  • BEHAVIORAL Laughter Therapy

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2018-04-01
Est. Completion 2019-03-28
Phase NA
Satellite Healthcare

18 total trials

What the finished NCT04098627 record still lists

NCT04098627 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 1 intervention - of which Laughter Therapy is the first listed.

NCT04098627 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04098627 about?

NCT04098627 is a clinical study titled "The Effects of Laughter Therapy on Hemodialysis on Depression". End stage kidney disease is associated with increased depression. Laughter is associated with improvement in depression in chronic disease. The study objective was to measure the effect of intradialytic group laughter therapy on anxiety and depression. Pragmatic randomized controlled trial conducted...

What is the current status of trial NCT04098627?

This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2018-04-01. Estimated completion is 2019-03-28.

What interventions are being tested in trial NCT04098627?

The interventions under investigation include: Laughter Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT04098627?

This trial is sponsored by Satellite Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04098627's enrollment target sits among peer trials

152 658th of 2000 higher than 1,340 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03328078 · 152 participants · Phase 1

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • NCT04458532 · 152 participants · NA

    Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

  • NCT04858334 · 152 participants · Phase 2

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  • NCT04993859 · 152 participants

    Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04098627, the US trial registry maintained by the National Library of Medicine. NCT04098627 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.